ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Tuesday, November 14, 2023

4:00PM-5:30PM: Abstract Number: 2552

Inflammatory Fibrosis Precedes Loss of Kidney Function in Lupus Nephritis

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes III: Disease Activity

4:00PM-5:30PM: Abstract Number: 2513

Latent Class Analysis Identifies 2 Clinical Phenotypes of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis

Abstracts: Immunological Complications of Medical Therapy

4:00PM-5:30PM: Abstract Number: 2548

Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment III: AxSpA

4:00PM-5:30PM: Abstract Number: 2515

Machine Learning-Based Stratification of Mixed Connective Tissue Disease Using Immunophenotyping Data from Patients with Related Autoimmune Diseases

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II

4:00PM-5:30PM: Abstract Number: 2544

Microbial Metabolism of Methotrexate Contributes to Its Pharmacokinetics in Vivo

Abstracts: RA – Treatments III: Predictors of Response & Tapering

4:00PM-5:30PM: Abstract Number: 2514

Myositis Triad Subset Is Associated with High Mortality in Immune Checkpoint Inhibitor- Induced Myositis

Abstracts: Immunological Complications of Medical Therapy

4:00PM-5:30PM: Abstract Number: 2532

Prevalence and Disease-Specific Factors Associated with Osteoporosis in Systemic Sclerosis: A Cross-Sectional Analysis of Two Large European Cohorts

Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science

4:00PM-5:30PM: Abstract Number: 2553

Prevalence, Determinants and Outcomes of Target Attainment in SLE Patients with Clinically Active Disease in a Large Multinational Prospective Lupus Cohort

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes III: Disease Activity

4:00PM-5:30PM: Abstract Number: 2531

Proton Pump Inhibitor Use Is Associated with Impaired Bone Mineral Density but Not Bone Microarchitecture in Patients with Inflammatory Rheumatic and Musculoskeletal Diseases Taking Glucocorticoids

Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science

4:00PM-5:30PM: Abstract Number: 2533

Real-world Evidence for Assessing Mortality Disparity Between the Patients with Rheumatoid Arthritis and the General Population in Japan: Results from the IORRA Study

Abstracts: Patient Outcomes, Preferences, & Attitudes II: Patient Experience

4:00PM-5:30PM: Abstract Number: 2523

Region, Race, and Hospital Factors Impact Length of Stay and Hospital Charges Post-primary Total Knee Arthroplasty

Abstracts: Orthopedics, Low Back Pain, & Rehabilitation

4:00PM-5:30PM: Abstract Number: 2524

Relation of Pain Sensitivity to Forces While Walking in Adults with and Without Knee Pain: The Multicenter Osteoarthritis (MOST) Study

Abstracts: Orthopedics, Low Back Pain, & Rehabilitation

4:00PM-5:30PM: Abstract Number: 2551

Remission and Low Disease Activity (LDA) in Patients with SLE Treated with Belimumab (BEL): Results from a Large Integrated Analysis

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes III: Disease Activity

4:00PM-5:30PM: Abstract Number: 2530

Risk Evaluation of Osteoporotic Fractures Following Lung Transplantation (LT): A Retrospective Cohort Study Conducted at an International Transplant Center

Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science

4:00PM-5:30PM: Abstract Number: 2509

Risk Factors and Mortality of Immune Checkpoint Inhibitor-Induced Flares of Pre-Existing Rheumatoid Arthritis: An Analysis Accounting for Competing Risk of Death and Immortal Time Bias

Abstracts: Immunological Complications of Medical Therapy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].